Your browser doesn't support javascript.
loading
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.
Quixabeira, D C A; Pakola, S; Jirovec, E; Havunen, R; Basnet, S; Santos, J M; Kudling, T V; Clubb, J H A; Haybout, L; Arias, V; Grönberg-Vähä-Koskela, S; Cervera-Carrascon, V; Kerkelä, E; Pasanen, A; Anttila, M; Tapper, J; Kanerva, A; Hemminki, A.
Affiliation
  • Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Pakola S; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Santos JM; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Haybout L; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Cervera-Carrascon V; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Kerkelä E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Pasanen A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Anttila M; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Tapper J; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Hemminki A; TILT Biotherapeutics Ltd, Helsinki, Finland.
Cancer Gene Ther ; 30(12): 1679-1690, 2023 12.
Article in En | MEDLINE | ID: mdl-37949944
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Hematopoietic Stem Cell Transplantation Limits: Animals / Female / Humans Language: En Journal: Cancer Gene Ther Journal subject: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Year: 2023 Type: Article Affiliation country: Finland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Hematopoietic Stem Cell Transplantation Limits: Animals / Female / Humans Language: En Journal: Cancer Gene Ther Journal subject: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Year: 2023 Type: Article Affiliation country: Finland